Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in Brazil, Colombia and Taiwan Galafold on …